Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 570

1.

First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial.

Colao A, Pivonello R, Rosato F, Tita P, De Menis E, Barreca A, Ferrara R, Mainini F, Arosio M, Lombardi G.

Clin Endocrinol (Oxf). 2006 Mar;64(3):342-51.

PMID:
16487447
2.

Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?

Jallad RS, Musolino NR, Kodaira S, Cescato VA, Bronstein MD.

Clin Endocrinol (Oxf). 2007 Aug;67(2):310-5. Epub 2007 Jun 6.

PMID:
17555503
3.

Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.

Jallad RS, Musolino NR, Salgado LR, Bronstein MD.

Clin Endocrinol (Oxf). 2005 Aug;63(2):168-75.

PMID:
16060910
4.

Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study.

Colao A, Cappabianca P, Caron P, De Menis E, Farrall AJ, Gadelha MR, Hmissi A, Rees A, Reincke M, Safari M, T'Sjoen G, Bouterfa H, Cuneo RC.

Clin Endocrinol (Oxf). 2009 May;70(5):757-68. doi: 10.1111/j.1365-2265.2008.03441.x. Epub 2008 Oct 6.

PMID:
19178516
5.

Predicting therapeutic response and degree of pituitary tumour shrinkage during treatment of acromegaly with octreotide LAR.

Jenkins PJ, Emery M, Howling SJ, Evanson J, Besser GM, Monson JP.

Horm Res. 2004;62(5):227-32. Epub 2004 Oct 11.

PMID:
15477693
6.

Octreotide LAR for the treatment of acromegaly.

Vallette S, Serri O.

Expert Opin Drug Metab Toxicol. 2008 Jun;4(6):783-93. doi: 10.1517/17425255.4.6.783 . Review.

PMID:
18611118
7.

Efficacy of Sandostatin LAR (long-acting somatostatin analogue) is similar in patients with untreated acromegaly and in those previously treated with surgery and/or radiotherapy.

Ayuk J, Stewart SE, Stewart PM, Sheppard MC; European Sandostatin LAR Group.

Clin Endocrinol (Oxf). 2004 Mar;60(3):375-81.

PMID:
15009004
8.

Investigation into the efficacy and safety of octreotide LAR in Japanese patients with acromegaly: Shizuoka study.

Oki Y, Inoue T, Imura M, Tanaka T, Genma R, Iwabuchi M, Hataya Y, Matsuzawa Y, Iino K, Nishizawa S, Nakamura H.

Endocr J. 2009;56(9):1095-101. Epub 2009 Sep 16.

9.

Forty month follow-up of persistent and difficultly controlled acromegalic patients treated with depot long acting somatostatin analog octreotide.

Yetkin DO, Boysan SN, Tiryakioglu O, Yalin AS, Kadioglu P.

Endocr J. 2007 Jun;54(3):459-64. Epub 2007 May 9.

10.

Sandostatin LAR in acromegaly: a 6-week injection interval suppresses GH secretion as effectively as a 4-week interval.

Biermasz NR, van den Oever NC, Frölich M, Arias AM, Smit JW, Romijn JA, Roelfsema F.

Clin Endocrinol (Oxf). 2003 Mar;58(3):288-95.

PMID:
12608933
11.

A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly.

Mercado M, Borges F, Bouterfa H, Chang TC, Chervin A, Farrall AJ, Patocs A, Petersenn S, Podoba J, Safari M, Wardlaw J; SMS995B2401 Study Group.

Clin Endocrinol (Oxf). 2007 Jun;66(6):859-68. Epub 2007 Apr 25.

13.

Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.

Plöckinger U, Quabbe HJ.

Acta Neurochir (Wien). 2005 May;147(5):485-93; discussion 493. Epub 2005 Apr 4.

PMID:
15806331
14.

Short-term preoperative octreotide treatment of GH-secreting pituitary adenoma: predictors of tumor shrinkage.

Oshino S, Saitoh Y, Kasayama S, Arita N, Ohnishi T, Kohara H, Izumoto S, Yoshimine T.

Endocr J. 2006 Feb;53(1):125-32.

15.

Clinical and biochemical response following withdrawal of a long-acting, depot injection form of octreotide (Sandostatin-LAR).

Stewart PM, Stewart SE, Clark PM, Sheppard MC.

Clin Endocrinol (Oxf). 1999 Mar;50(3):295-9.

PMID:
10435053
16.

Growth hormone isoforms in acromegalic patients before and after treatment with octreotide LAR.

Lima GA, Wu Z, Silva CM, Barbosa FR, Dias JS, Schrank Y, Strasburger CJ, Gadelha MR.

Growth Horm IGF Res. 2010 Apr;20(2):87-92. doi: 10.1016/j.ghir.2009.10.001. Epub 2009 Nov 1.

PMID:
19884028
17.

Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly.

Turner HE, Thornton-Jones VA, Wass JA.

Clin Endocrinol (Oxf). 2004 Aug;61(2):224-31.

PMID:
15272918
18.

Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size.

Bevan JS, Atkin SL, Atkinson AB, Bouloux PM, Hanna F, Harris PE, James RA, McConnell M, Roberts GA, Scanlon MF, Stewart PM, Teasdale E, Turner HE, Wass JA, Wardlaw JM.

J Clin Endocrinol Metab. 2002 Oct;87(10):4554-63.

PMID:
12364434
19.

Octreotide lar affects the volume of pituitary adenoma in acromegalic patients.

Bałdys-Waligórska A, Krzentowska-Korek A, Gołkowski F, Sokołowski G, Hubalewska-Dydejczyk A.

Exp Clin Endocrinol Diabetes. 2011 May;119(5):295-9. doi: 10.1055/s-0030-1267249. Epub 2011 Jan 24.

PMID:
21264808
20.

Long-term octreotide therapy in growth hormone-secreting pituitary adenomas: evaluation with serial MR.

Lundin P, Edén Engström B, Karlsson FA, Burman P.

AJNR Am J Neuroradiol. 1997 Apr;18(4):765-72.

Supplemental Content

Support Center